20240105_PYFA_Ringkasan Risalah//Risalah RUPS_31565108_lamp1.pdf

     point sixty six percent) from the total of 535.080.000 (five hundred thirty five million and eighty
     thousand) shares with valid voting rights issued by the Company.

E. In the Meeting, each Shareholder/proxy was given the opportunity to ask questions and/or
   provide opinions, related to each Meeting agenda.

F. The decision-making mechanism in the Meeting is as follows:
   Meeting decisions were made by way of deliberation to reach consensus, if there were
   shareholders or their proxies who vote against or abstain, voting would be made electronically
   through eASY.KSEI or physically (by way of show of hand for those against)..

G. The number of shareholders or its proxy who asked questions and/or provided opinions as well
   as the results of the voting on the agenda of the Meeting is as follows :


                         The number of                               Voting Results
                      Shareholders/Proxies
         Meeting
                      who asked questions
         Agenda                                        Affirmative           Dissenting      Abstain
                         and/or provide
                           opinions
                                                  378,073,109 shares
                                                                            2.100 shares
             1                   2                 (99,99% of those                              0
                                                                               (0,01%)
                                                       present)
                                                  378,075,109 shares
                                                                             100 shares
             2                   2                 (99,99% of those                              0
                                                                              (0,01%)
                                                       present)


H.   Whereas in the Company’s Meeting the following decisions have been made with unanimous
     votes:

     Meeting Agenda 1:

     1. Approval for the issuance of new shares by the Company, by granting Preemptive Right I Year
        2024 (or PMHMETD I) based on the Financial Services Authority Regulation No.
        32/POJK.04/2015 concerning the Increase of Capital for Public Companies by Providing The
        Right Issue, as amended by Financial Services Authority Regulation No. 14/POJK.04/2019. The
        issuance involves a maximum of 16,000,000,000 (sixteen billion) shares with a nominal value
        of Rp100 (one hundred Rupiah) per share;
     2. Approval to authorize the Company's Board of Directors to undertake all necessary actions
        regarding with PMHMETD I, in compliance with the conditions stipulated in the prevailing laws
        and regulations, including capital market regulations, including but not limited to:
         a. Determining all conditions and provisions for the implementation of PMHMETD I, including
             but not limited to the certainty of the number of shares issued in the context of PMHMETD
             I, and the exercise price in the context of PMHMETD I;
         b. Signing the necessary documents, including notarial deeds and registration statement
             documents to the Financial Services Authority (OJK);
         c. Determining the Record Date (List of Shareholders) for entitlement to PMHMETD I;
         d. Setting the schedule for PMHMETD I;
         e. Establishing the ratios of shareholders entitled to PMHHMETD I;
         f. Ensuring the use of funds from the proceeds of PMHMETD I;

    g. Determining standby buyers, as well as specifying the terms and conditions and signing all
       deeds and/or agreements and/or documents between the Company and standby buyers.

Meeting Agenda 2:

1. Approval for the amendment of Article 4 paragraph 1 of the Company's Articles of Association
   by increasing the Company's authorized capital to Rp3,800,000,000,000 (three trillion eight
   hundred billion Rupiah), divided into 38,000,000,000 (thirty-eight billion) shares, each with a
   nominal value of Rp100 (one hundred Rupiah);
2. In connection with the amendment of Article 4 paragraph 1 of the Company's Articles of
   Association, approval is granted to authorize the Company's Board of Directors (with
   substitution rights) to declare it in a separate deed before a notary. Subsequently, the Board is
   empowered to submit an application for approval of the amendment to the Company's Articles
   of Association to the Minister of Law and Human Rights of the Republic of Indonesia. This
   includes making any changes and/or additions in any form deemed necessary for the
   aforementioned purpose, submitting and signing all other applications and documents, and
   executing any other actions that may be required;
3. Approval for the amendment of Article 4 paragraph 2 of the Company's Articles of Association
   regarding the increase in the issued and paid-up capital of the Company in connection with the
   implementation of PMHMETD I; and
4. In connection with the amendment of Article 4 paragraph 2 of the Company's Articles of
   Association, approval is granted to authorize the Company's Board of Directors (with
   substitution rights) to declare the increase in subscribed and paid-up capital, specifically the
   amendment to Article 4 paragraph 2 of the Company's Articles of Association after the
   completion of PMHMETD I. Subsequently, the Board is empowered to submit a notification of
   the amendment to the Company's Articles of Association to the Minister of Law and Human
   Rights of the Republic of Indonesia. This includes making any changes and/or additions in any
   form deemed necessary for the aforementioned purpose, submitting and signing all other
   applications and documents, and executing any other actions that may be required.

                                  Jakarta, 08 January 2024
                        The Board of Directors PT Pyridam Farma Tbk.